首页> 外文期刊>Therapeutic Drug Monitoring >Population pharmacokinetics of carbamazepine in chinese epilepsy patients.
【24h】

Population pharmacokinetics of carbamazepine in chinese epilepsy patients.

机译:卡马西平在中国癫痫患者中的群体药代动力学

获取原文
获取原文并翻译 | 示例
           

摘要

AIMTo investigate the pharmacokinetic profile of carbamazepine (CBZ) in Chinese epilepsy patients.MATERIALS AND METHODSSerum samples through concentrations at steady state (n = 687) were collected prospectively from 585 patients during routine clinical care. Data were analyzed by the non-linear mixed-effect modeling (NONMEM) technique with a one-compartment model of first-order absorption and elimination.RESULTSThe important determinants of clearance (CL) were total body weight (TBW); dose; patient age over 65 years (E); and comedication with phenytoin (PHT), phenobarbital (PB), or valproic acid (VPA) when VPA daily dose was greater than 18 mg/kg. The final pharmacokinetic model for relative CL and apparent distribution volume (V) were: Equation CONCLUSIONA population pharmacokinetic model was proposed to estimate the individual CL for Chinese patients receiving CBZ in terms of patient's dose, TBW, and comedications to establish a priori dosage regimens.
机译:目的探讨卡马西平(CBZ)在中国癫痫患者中的药代动力学特征。材料与方法前瞻性收集了585名患者在常规临床治疗中的稳态稳态血清浓度(n = 687)。采用非线性混合效应模型(NONMEM)技术对一阶吸收和消除的一室模型进行数据分析。结果清除率(CL)的重要决定因素是体重(TBW)。剂量;患者年龄超过65岁(E);当VPA日剂量大于18 mg / kg时,应使用苯妥英钠(PHT),苯巴比妥(PB)或丙戊酸(VPA)进行矫形。最终的相对CL和表观分布体积(V)的药代动力学模型为:公式结论提出了一种群体药代动力学模型,以根据患者的剂量,TBW和药物来估算接受CBZ的中国患者的个体CL,以建立先验剂量方案。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号